Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Happle, N. Lachmann, M. Wetzke, D. Lüttge, M. Ackermann, A. Mucci, J. Skuljec, S. Merkert, A. Schambach, T. Moritz, G. Hansen (Hannover, Germany). Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies. Eur Respir J 2013; 42: Suppl. 57, 689

Member's Comments

No comment yet.

Related content which might interest you: Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Alveolar type II cells transplantation in pulmonary fibrosis: Effect on the lung macrophage activation Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The effects of tobramycin on pulmonary fibroblast function Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 The effect of in vitro culture methods on corticosteroid sensitivity in COPD alveolar macrophages Source: Annual Congress 2013 –COPD: experimental biology Year: 2013 Characterization of M1 and M2 macrophages in human lung tissue Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary alveolar proteinosis due to heterozygous mutation in OAS1: Treatment of a novel disease with whole lung lavages and stem cell transplantation Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans Year: 2019 Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of HGF in the healthy and injured lung Source: International Congress 2015 – IIPs: orphan Year: 2015 Late Breaking Abstract - Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through systemic modulation of monocyte phenotypes Source: International Congress 2018 – ILDs: From bench to bedside Year: 2018 Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Induced pluripotent stem cells conditioned media (iPS-cm) modulates macrophage phenotype in the fibrotic lung Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 The use of immunohistochemical stains to identify Langerhans cells in pulmonary histiocytosis Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 The secretome of induced pluripotent stem cells (iPSC) modulates macrophage phenotype in the fibrotic lung Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015